Skip to content

Allan Blemings

5 papers in the library · 1,643 citations · publishing 2020-2026

Papers

Sort Most recent Most cited

Psilocybin therapy for adult females with anorexia nervosa: pilot study.

The British Journal of Psychiatry July 8, 2026 Hannah Douglass, Meg J. Spriggs, Kate Godfrey et al.

Background Anorexia nervosa is a debilitating eating disorder with high mortality and chronicity rates owing to the paucity of effective existing treatments. Several clinical trials using psilocybin therapy have demonstrated therapeutic efficacy and safety in psychiatric conditions, including anorexia nervosa. Aims This study aimed to further assess the safety, feasibility and potential...

Study Protocol for “Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study”

Frontiers in Psychiatry October 20, 2021 Meg J. Spriggs, Hannah Douglass, Rebecca J. Park et al. 78 citations

Background: Anorexia nervosa (AN) is a serious and life-threatening psychiatric condition. With a paucity of approved treatments, there is a desperate need for novel treatment avenues to be explored. Here, we present (1) an overview of the ways through which Public Patient Involvement (PPI) has informed a trial of psilocybin-assisted therapy for AN and (2) a protocol for a pilot study of...

DOI: 10.3389/fpsyt.2021.735523 (opens in new tab) Psilocybin Anorexia nervosa Protocol science Psychopathology +4

Trial of Psilocybin versus Escitalopram for Depression

New England Journal of Medicine April 14, 2021 Robin Carhart-Harris, Bruna Giribaldi, Rosalind Watts et al. 1,372 citations

On the basis of the change in depression scores on the QIDS-SR-16 at week 6, this trial did not show a significant difference in antidepressant effects between psilocybin and escitalopram in a selected group of patients. Secondary outcomes generally favored psilocybin over escitalopram, but the analyses of these outcomes lacked correction for multiple comparisons. Larger and longer trials are...

DOI: 10.1056/nejmoa2032994 (opens in new tab) Psilocybin Hallucinogen Escitalopram Depression economics

Self-blinding citizen science to explore psychedelic microdosing.

Elife March 2, 2021 Balázs Szigeti, Laura Kärtner, Allan Blemings et al. 192 citations

Microdosing is the practice of regularly using low doses of psychedelic drugs. Anecdotal reports suggest that microdosing enhances well-being and cognition; however, such accounts are potentially biased by the placebo effect. This study used a 'self-blinding' citizen science initiative, where participants were given online instructions on how to incorporate placebo control into their...

Author response: Self-blinding citizen science to explore psychedelic microdosing

December 11, 2020 Balázs Szigeti, Laura Kärtner, Allan Blemings et al. 1 citation

Psychedelic psychotherapy, therapy enhanced with psychedelic drugs such as LSD or psilocybin (the active ingredient of ‘magic mushrooms’), has been suggested to improve psychological well-being. For this reason, trials on psychedelic therapy for the treatment of depression, addiction and other conditions are ongoing. Recently, ‘microdosing’ – a way of administering psychedelics that involves...